Taconic Biosciences' Randi Lundberg, DVM, PhD penned this article in The Journal of Precision Medicine "regarding the microbiome's effect on tumor growth and targeted therapeutics, including immunotherapies such as checkpoint inhibitors":
"Research has progressed from demonstrating a link between the microbiome and cancer therapy in mice, to supporting those findings in human patients, to opening new possibilities to explore modulation of the microbiome as a personalized medicine strategy for improving immunotherapy efficacy.
Some of the first studies to demonstrate a connection between the microbiome and response to cancer treatment in mice were published in 2013." Read the complete article at: TheJournalofPrecisionMedicine.com
"Research has progressed from demonstrating a link between the microbiome and cancer therapy in mice, to supporting those findings in human patients, to opening new possibilities to explore modulation of the microbiome as a personalized medicine strategy for improving immunotherapy efficacy.Some of the first studies to demonstrate a connection between the microbiome and response to cancer treatment in mice were published in 2013."